PLS3 Antibody

What is PLS3 and why is it significant in research?

PLS3 (Plastin 3) is an actin-binding protein that belongs to the plastin family, which is conserved throughout eukaryote evolution and expressed in most tissues of higher eukaryotes. In humans, there are three distinct plastin isoforms with specific tissue distribution patterns. The L isoform is expressed only in hemopoietic cell lineages, while the T isoform (PLS3) has been found in normal cells of solid tissues that have replicative potential, including fibroblasts, endothelial cells, epithelial cells, and melanocytes. Plastin 1 (also known as Fimbrin) is specifically expressed at high levels in the small intestine .

PLS3 has emerged as a significant biomarker in cancer research, particularly for identifying circulating tumor cells (CTCs) in peripheral blood. Studies have demonstrated that PLS3 may serve as an excellent biomarker for identifying groups at risk of recurrence or with a poor prognosis in cancers such as breast cancer . The protein contains a potential calcium-binding site near the N terminus, and alternate splicing results in multiple transcript variants. With an observed molecular weight of approximately 71 kDa, PLS3 represents an important target for antibody-based detection methods in various research applications .

What are the different types of PLS3 antibodies available for research?

Researchers have access to a diverse array of PLS3 antibodies with varying characteristics to suit different experimental needs:

Host Species and Clonality:

• Rabbit polyclonal antibodies targeting various epitopes of PLS3

• Mouse monoclonal antibodies (e.g., clone 5B9)

Target Regions:

PLS3 antibodies target different amino acid regions of the protein, including:

• AA 5-251 (e.g., ABIN7439222)

• AA 1-240

• AA 234-475

• AA 310-455

• AA 379-630

• AA 401-500

• AA 503-552

• Full-length (AA 1-630)

Species Reactivity:

• Human-specific antibodies

• Mouse-specific antibodies

• Multi-species reactive antibodies (cross-reactive with Human, Mouse, Rat, etc.)

The selection of the appropriate PLS3 antibody should be guided by the specific requirements of the experiment, including target species, application method, and the epitope of interest. Some antibodies have been validated using knockout/knockdown methodologies, which provides additional confidence in their specificity .

Which applications are PLS3 antibodies suitable for?

PLS3 antibodies have been validated for multiple research applications, allowing researchers to study this protein in various experimental contexts:

Common Applications and Recommended Dilutions:

• Western Blotting (WB): For detecting PLS3 protein in cell or tissue lysates (1:500-1:2000 dilution)

• Immunohistochemistry (IHC): For visualizing PLS3 in tissue sections (1:50-1:200 dilution)

• Immunocytochemistry (ICC): For detecting PLS3 in cultured cells

• Immunoprecipitation (IP): For isolating PLS3 protein complexes

• Enzyme-Linked Immunosorbent Assay (ELISA): For quantitative detection of PLS3

• Immunofluorescence (IF): For fluorescent visualization of PLS3 (1:50-1:200 dilution)

Different antibodies may perform optimally in specific applications, so researchers should select antibodies that have been validated for their intended use. The recommended dilutions provide starting points for optimization, but researchers should perform titration experiments to determine the optimal concentration for their specific experimental conditions .

How should PLS3 antibodies be stored for optimal performance?

Proper storage of PLS3 antibodies is crucial for maintaining their activity and specificity over time:

Storage Conditions:

• Temperature: -20°C for up to 12 months

• Buffer composition: PBS with 0.02% sodium azide and 50% glycerol at pH 7.3

• Avoid repeated freeze/thaw cycles that can degrade antibody performance

Best Practices:

• Aliquot antibodies upon receipt to minimize freeze/thaw cycles

• Thaw antibodies completely before use and mix gently

• Return to storage promptly after use

• Follow manufacturer's specific recommendations, as storage conditions may vary between different products

Adhering to these storage guidelines will help ensure consistent antibody performance throughout the duration of a research project. Proper storage is especially important for maintaining the high specificity required for applications such as immunohistochemistry and Western blotting .

What controls should be used when working with PLS3 antibodies?

Including appropriate controls is essential for validating results obtained with PLS3 antibodies:

Positive Controls:

• Cell lines with confirmed PLS3 expression, such as:

  • MDA-MB-231 (E/M phenotype)

  • Hs578t (mesenchymal phenotype)

  • MCF-7 (luminal phenotype)

  • MDA-MB-468 (basal phenotype)

  • BC-M1 (disseminating breast cancer cell line with particularly high PLS3 expression)

Negative Controls:

• Peripheral blood mononuclear cells (PBMCs) from healthy individuals, which show undetectable levels of PLS3 expression by Western blotting and qRT-PCR

• Isotype controls (appropriate IgG from the same species as the primary antibody)

• Secondary antibody-only controls to assess background

Technical Controls:

• Antibody validation using knockdown/knockout systems

• Peptide competition assays using the immunogen

• Multiple antibody validation using antibodies targeting different epitopes

These control measures help ensure the specificity and reliability of results obtained with PLS3 antibodies and are particularly important when establishing new protocols or applying these antibodies to novel experimental systems .

How can PLS3 antibodies be used to detect circulating tumor cells (CTCs)?

PLS3 antibodies have proven valuable for detecting circulating tumor cells in peripheral blood, which has important implications for cancer prognosis and monitoring:

Immunocytochemical Detection:

• Process blood samples to isolate the mononuclear cell fraction containing potential CTCs

• Fix and permeabilize cells according to standard protocols

• Stain with PLS3 antibodies (dilutions typically 1:50-1:200 for immunofluorescence)

• Counterstain nuclei and use appropriate secondary antibodies

• PLS3-positive CTCs can be visualized with specific signals observable around the nucleus and in the cytoplasm

Molecular Detection:

• Extract RNA from peripheral blood samples

• Perform quantitative RT-PCR to detect PLS3 mRNA expression

• Use receiver operating characteristic (ROC) curves to determine appropriate cutoff values for PLS3 positivity

• Compare with clinical outcomes to validate prognostic significance

Studies have demonstrated that tumor cells are clearly distinguishable from normal blood cells based on differences in PLS3 expression, making this a robust approach for CTC detection in research settings. The methodology has been successfully applied to identify patients at higher risk of recurrence or with poor prognosis in breast cancer studies .

What are the methodological considerations for using PLS3 antibodies in immunohistochemistry?

Successful immunohistochemistry with PLS3 antibodies requires attention to several critical methodological factors:

Sample Preparation:

• Fixation: Use appropriate fixatives (typically formalin) and optimize fixation time

• Embedding: Follow standard protocols for paraffin embedding or frozen section preparation

• Sectioning: Prepare sections of appropriate thickness (typically 4-5 μm)

• Antigen retrieval: May be necessary to unmask epitopes (methods should be optimized)

Staining Protocol:

• Antibody dilution: Typically 1:50-1:200 for IHC applications

• Blocking: Use appropriate blocking agents to reduce background staining

• Incubation conditions: Optimize time and temperature for primary and secondary antibodies

• Detection systems: Select appropriate visualization methods (DAB, AEC, etc.)

Controls and Validation:

• Include positive and negative tissue controls in each experiment

• Use isotype controls to assess non-specific binding

• Consider serial dilutions to confirm specificity and determine optimal concentration

Interpretation:

• Establish clear scoring criteria for PLS3 positivity

• Document subcellular localization (cytoplasmic vs. nuclear)

• Consider both staining intensity and percentage of positive cells

Following these methodological considerations will help ensure reliable and reproducible IHC results when using PLS3 antibodies for tissue-based research applications .

How does PLS3 expression correlate with clinical outcomes in cancer research?

Research has revealed significant correlations between PLS3 expression and clinical outcomes in cancer patients, particularly in breast cancer:

Clinical Correlations:

• PLS3 positivity showed significant associations with specific breast cancer subtypes:

  • 69.8% of HER2-negative patients vs. 55.1% of HER2-positive patients (P = 0.0313)

  • 76% of PgR-negative patients vs. 41.0% of PgR-positive patients (P = 0.0008)

  • 74% of triple-negative breast cancer patients vs. 37.3% of patients with other subtypes (P = 0.023)

Prognostic Value in Early-Stage Disease:

• Even in breast cancer cases without lymph node metastasis, PLS3-positive patients showed significantly poorer OS and DFS than PLS3-negative individuals

This data strongly supports the value of PLS3 as an independent prognostic marker in cancer research, particularly for identifying high-risk patients even in early-stage disease. The table below summarizes the univariate and multivariate analysis results:

These findings demonstrate the robust prognostic value of PLS3 in cancer research .

What are the optimal conditions for Western blotting using PLS3 antibodies?

Achieving optimal Western blotting results with PLS3 antibodies requires careful attention to several experimental parameters:

Sample Preparation:

• Use appropriate lysis buffers containing protease inhibitors

• Determine optimal protein loading amount (typically 20-50 μg of total protein)

• Include positive control samples known to express PLS3 (e.g., MDA-MB-231, Hs578t, MCF-7, MDA-MB-468, BC-M1 cell lines)

Gel Electrophoresis:

• Use SDS-PAGE gels with appropriate acrylamide percentage (typically 8-10% for PLS3 detection)

• Ensure adequate separation time for resolving the target protein (PLS3 observed molecular weight: approximately 71 kDa)

Transfer and Blocking:

• Optimize transfer conditions for efficient transfer of proteins

• Block membranes thoroughly to reduce background (5% non-fat milk or BSA in TBST is commonly used)

Antibody Incubation:

• Primary PLS3 antibody: Use at 1:500 to 1:2000 dilution

• Secondary antibody: Typically 1:2000 to 1:10000 dilution

• Optimize incubation time and temperature (typically overnight at 4°C for primary antibody)

Detection:

• Choose appropriate detection method (chemiluminescence, fluorescence, etc.)

• Adjust exposure time to obtain optimal signal-to-noise ratio

• Verify specificity by observing a band at the expected molecular weight (71 kDa)

Following these optimized conditions will help ensure specific and sensitive detection of PLS3 protein by Western blotting, which is crucial for quantitative analysis of expression levels in experimental samples .

How can specificity of PLS3 antibodies be validated in experimental settings?

Validating the specificity of PLS3 antibodies is essential for ensuring reliable experimental results:

Genetic Validation Approaches:

• Compare antibody signals between wild-type cells and cells where PLS3 has been knocked down (siRNA, shRNA) or knocked out (CRISPR/Cas9)

• A specific antibody will show reduced or absent signal in knockdown/knockout samples

• Some commercial antibodies are already knockout-validated, providing additional confidence in their specificity

Biochemical Validation:

• Peptide competition assay: Pre-incubate the antibody with excess immunizing peptide before application

• Multiple antibody validation: Use antibodies targeting different epitopes of PLS3 and compare detection patterns

• Immunoprecipitation-mass spectrometry: Confirm the identity of the precipitated protein

Expression Correlation:

• Compare protein detection by antibodies with mRNA expression levels using qRT-PCR

• In breast cancer studies, concordant results between PLS3 protein detection and mRNA expression have been observed

• Verify expression patterns across multiple cell types (e.g., high expression in certain cancer cell lines, low/absent expression in PBMCs)

Application-Specific Validation:

• Test antibody performance across different applications (WB, IHC, ICC, etc.)

• Optimize conditions for each application

• Include appropriate positive and negative controls in each experiment

Implementing these validation approaches helps ensure that experimental results obtained with PLS3 antibodies are reliable and specific, which is particularly important when using these antibodies in novel research contexts or clinical applications .